CCS Cardiometabolic Research Award
The Canadian Cardiovascular Society (CCS), Heart & Stroke / Richard Lewar Centre of Excellence in Cardiovascular Research (HSRLCE), the BI-Lilly Alliance, and Novo Nordisk have collaboratively created an award, entitled “CCS/HSRLCE/BI-Lilly/Novo Nordisk Cardiometabolic Research Award”.
This Award is intended for early career researchers (including PhDs and MDs) who are within five (5) years of their first faculty appointment at a Canadian academic institution, for a research project on any topic related to cardiometabolic disease.
A single award of $30K will be awarded based on an independent peer review process. Funded research must be completed within 12 months from the start of funding.
Call for Applications: Closed
- Be a CCS Member*. For more information about CCS Membership, visit the CCS website: https://ccs.ca/membership/.
*You must be a CCS member to accept funding, but you can apply without being a member!
- Applicants must an early career researcher (including PhDs and MDs) within five years of their first faculty appointment at a Canadian academic institution.
- Applicants must be a Canadian Citizen or Permanent Resident of Canada at the time of receiving funding.
- Award funds are solely intended for research performed in Canada.
- The award and funds are intended for original research and should not supplement funding for an ongoing project.
- If the submission refers to a multicenter clinical trial, the applicant must specify their specific role in the research study.
- If the application is for a sub-study of an ongoing project or trial, the applicant must specify their role and explain how the sub-study is distinct from the main study.
- Funded research must be completed within 12 months from the start of funding.
- Research status report will be requested and should be submitted on October 1st of the ensuing year(s) that the project is running.
- Upon completion of the project, there is an expectation that the output of the research be submitted for presentation at cardiovascular congresses like the CCC. The submission must acknowledge the source of the research funding, the CCS/HSRLCE/BI-Lilly/Novo Nordisk Cardiometabolic Research Award.
One (1) award is available in 2023.
Funds will be administered by the Cardiology Division of the awardee’s affiliated university or equivalent.
The Peer Review Process and Evaluation Committee
All applications will be pre-screened for eligibility. Applications that are late, incomplete and/or do not meet the basic eligibility criteria will not be considered for review.
Peer review of all eligible applications will be conducted by a scientific review committee comprised of CCS members selected for their subject matter expertise. All eligible proposals will be reviewed by at least two members of the peer review committee.
Evaluation of applications will be based on three (3) criteria: quality, and feasibility of project, quality of applicant, research environment and mentor.
If you have any questions or require support preparing or submitting your application, please email firstname.lastname@example.org.
The Canadian Cardiovascular Society, Heart & Stroke / Richard Lewar Centre of Excellence in Cardiovascular Research, the BI-Lilly Alliance, and Novo Nordisk are proud to support the CCS/HSRLCE/BI-Lilly/Novo Nordisk Cardiometabolic Research Award. With this award, we hope to further research on the link between cardiovascular disease in diabetes to improve thelives of Canadians who are affected by these conditions, and their families